Subgroup Analyses in the Treatment of Diabetic Nephropathy: A Meta-Analysis.

INTRODUCTION

This meta-analysis synthesizes and evaluates treatments for diabetic nephropathy, focusing on subgroup analyses to understand efficacy variations across diverse patient demographics and disease characteristics, thereby advancing personalized healthcare in diabetic kidney disease.

METHODS

Adhering to PRISMA guidelines, a thorough literature search across PubMed, NCBI, and Web of Science initially identified 904 studies spanning from 2015 to 2023. A meticulous screening process, involving the review of titles and abstracts and the application of stringent inclusion and exclusion criteria, refined the selection to six studies. These studies were selected for their comprehensive focus on diabetic nephropathy, availability of odds ratio data, and detailed subgroup analyses. Statistical synthesis was conducted using a random-effects model, and heterogeneity was assessed using the I² statistic.

RESULTS

Analysis of the selected studies revealed significant heterogeneity in treatment effectiveness related to patient demographics, nephropathy stages, genotypes, and other disease-specific characteristics. The overall estimated odds ratio (OR) for treatment efficacy was 2.7 (95% CI: 1.8-3.6), indicating a moderate effect size. This variation highlighted the complex interplay of genetic, environmental, and lifestyle factors in nephropathy treatment outcomes. The study also delved into the mechanistic aspects of treatment interactions with diverse nephropathy subtypes, thereby offering a deeper understanding of the efficacy of treatments within specific patient categories.

CONCLUSIONS

The study underscores the critical need for personalized treatment strategies in diabetic nephropathy, providing valuable insights for healthcare professionals. It advocates for tailoring treatments to individual patient profiles to optimize outcomes, enhancing patient care quality. These findings reinforce the value of subgroup-based approaches and support evidence-based, patient-centric management in diabetic kidney disease.